Verastem VSTM
Verastem, Inc. · Nasdaq · Pharmaceutical Preparations
$9.66-1.83%close on Oct. 29, 2026 · volume 1.9M · Yahoo Finance
Price, last 48 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 1, 2026 | Dan Paterson President and CEO, director | Sold 10b5-1 plan | 44,121 | $8.00 | $352,968 |
| Oct. 1, 2026 | Daniel Calkins Chief Financial Officer | Sold 10b5-1 plan | 2,566 | $8.00 | $20,528 |
| Sept. 21, 2026 | Daniel Calkins Chief Financial Officer | Sold 10b5-1 plan | 55 | $7.70 | $424 |
| Aug. 3, 2026 | Dan Paterson President and CEO, director | Sold 10b5-1 plan | 1,302 | $5.81 | $7,565 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 15 →Other events · Financial statements and exhibits
Results of operations and financial condition · Departure/appointment of directors or officers · Regulation FD disclosure · Other events · Financial statements and exhibits